Imaging Biomarkers in CNS Drug Development

被引:0
|
作者
Tauscher, J. [1 ]
Schwarz, A. [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:34 / 35
页数:2
相关论文
共 50 条
  • [1] The utility of biomarkers in CNS drug development
    Palmer, Alan M.
    DRUG DISCOVERY TODAY, 2014, 19 (03) : 201 - 203
  • [2] Challenges in CNS drug development and the role of imaging
    Howes, Oliver D.
    Mehta, Mitul A.
    PSYCHOPHARMACOLOGY, 2021, 238 (05) : 1229 - 1230
  • [3] Challenges in CNS drug development and the role of imaging
    Oliver D. Howes
    Mitul A. Mehta
    Psychopharmacology, 2021, 238 : 1229 - 1230
  • [4] Magnetic resonance imaging in CNS drug development
    Luthringer, R
    Gilles, C
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S54 - S54
  • [5] Qualification of imaging biomarkers for oncology drug development
    Waterton, John C.
    Pylkkanen, Liisa
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 409 - 415
  • [6] Imaging biomarkers as surrogate endpoints for drug development
    Wolf S. Richter
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 6 - 10
  • [7] Imaging biomarkers as surrogate endpoints for drug development
    Richter, Wolf S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (Suppl 1) : S6 - S10
  • [8] Swings and Roundabouts in CNS Drug Biomarkers
    Isaac, M. B.
    Vamvakas, S.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2017, 4 (03): : 134 - 135
  • [9] The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development
    Dean F Wong
    Johannes Tauscher
    Gerhard Gründer
    Neuropsychopharmacology, 2009, 34 : 187 - 203
  • [10] The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development
    Wong, Dean F.
    Tauscher, Johannes
    Gruender, Gerhard
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (01) : 187 - 203